NCT06719310View on ClinicalTrials.gov

Phase Ib/IIa Clinical Study of ACC017 Tablets

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 28, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

November 30, 2025

Conditions
Infection, Human Immunodeficiency Virus
Interventions
DRUG

ACC017+FTC/TAF

ACC017+FTC/TAF

DRUG

Placebo

Placebo

Trial Locations (1)

Unknown

RECRUITING

Beijing Ditan Hospital, Capital Medical University, Beijing

Sponsors
All Listed Sponsors
collaborator

Chengdu Aidea Pharmaceutical Technology Co., Ltd

INDUSTRY

lead

Jiangsu Aidea Pharmaceutical Co., Ltd

INDUSTRY

NCT06719310 - Phase Ib/IIa Clinical Study of ACC017 Tablets | Biotech Hunter | Biotech Hunter